Game-Changing Updates on GLP-1 Medications: New Savings, Implants, and Telehealth Trends

In this episode of Downsized News, hosts Laraine and Christopher Durham provide the latest updates and insights on GLP-1 medications. Key topics include Eli Lilly's new savings program offering substantial discounts on Taltz and Zepbound, the anticipated launch of generic semaglutide in Canada by Sandoz Group in 2026, and breakthrough research on a new Exentatide implant for managing obesity. The episode also discusses ongoing shortages of Novo Nordisk's diabetic medications and the impact of telehealth trends on GLP-1 users. While highlighting essential reminders about consulting healthcare professionals before starting any new drug or treatment, the hosts invite viewers to join their live sessions and explore their supportive community resources.

JOIN CLUB DOWNSIZED: https://www.youtube.com/@thedownsized...

DOWNSIZED GLP-1 COMPANION PRODUCT STORE: https://thedownsized.org/downsized-st...

Start your weight loss journey today! We use Mochi Health: https://joinmochi.com/. Use Laraine’s code for $40 off: QIYGO8.

DOWNSIZED WEBSITE: https://thedownsized.org/

00:00 Introduction and Overview
01:32 Eli Lilly's New Savings Program
03:30 Novo Nordisk Supply Shortage
05:22 Innovative GLP-1 Implant by Vivante Medical
07:45 Telehealth Trends and GLP-1 Access
11:22 Upcoming Generic Semaglutide
13:23 Conclusion and Community Engagement